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Body Disorders
Martin Ingelsson*
Rudbeck Laboratory, Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden
Adverse intra- and extracellular effects of toxic α-synuclein are believed to be central to
the pathogenesis in Parkinson’s disease and other disorders with Lewy body pathology in
the nervous system. One of the physiological roles of α-synuclein relates to the regulation
of neurotransmitter release at the presynapse, although it is still unclear whether this
mechanism depends on the action of monomers or smaller oligomers. As for the
pathogenicity, accumulating evidence suggest that prefibrillar species, rather than the
deposits per se, are responsible for the toxicity in affected cells. In particular, larger
oligomers or protofibrils of α-synuclein have been shown to impair protein degradation as
well as the function of several organelles, such as the mitochondria and the endoplasmic
reticulum. Accumulating evidence further suggest that oligomers/protofibrils may have a
toxic effect on the synapse, which may lead to disrupted electrophysiological properties.
In addition, recent data indicate that oligomeric α-synuclein species can spread between
cells, either as free-floating proteins or via extracellular vesicles, and thereby act as seeds
to propagate disease between interconnected brain regions. Taken together, several lines
of evidence suggest that α-synuclein have neurotoxic properties and therefore should be
an appropriate molecular target for therapeutic intervention in Parkinson’s disease and
other disorders with Lewy pathology. In this context, immunotherapy with monoclonal
antibodies against α-synuclein oligomers/protofibrils should be a particularly attractive
treatment option.
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LEWY PATHOLOGY/α-SYNUCLEIN
At autopsy, widespread neuronal loss can be seen in the brain stem and neocortex of patients with
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and
the Lewy body variant of Alzheimer’s disease (LBAD). Collectively, these diseases are referred to
as Lewy body disorders. Intracellular protein inclusions, known as Lewy bodies and Lewy neurites,
can be seen in a portion of the surviving cells (Figure 1). For PD, DLB, and LBAD, most of such
deposits can be found in neurons, whereas inMSA they are mainly displayed in glial cells (reviewed
in Braak and Braak, 2000).
The principal component of the intraneuronal and intraglial inclusions is α-synuclein, a protein
of 140 amino acids that is ubiquitously expressed in neurons (Jakes et al., 1994). Whereas,
α-synuclein is intrinsically disordered in the cytosol, it adopts an alpha-helical conformation when
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FIGURE 1 | Neuropathology of Lewy body disorders. Lewy bodies and
Lewy neurites (arrows) in substantia nigra from a PD patient, stained with a
polyclonal antibody directed against α-synuclein amino acids 126–135
(20 × magnification). The arrows point toward Lewy bodies. The arrowhead
points toward a Lewy neurite. Scale bar = 50 µm. Photo: Leire Almandoz Gil,
Uppsala University.
it becomes bound to cellular membranes (Weinreb et al., 1996;
Kim, 1997; Chandra et al., 2003; Fauvet et al., 2012; Burre
et al., 2013). The normal function of α-synuclein has only been
partly understood, but because of its principal localization to
the synaptic region it has been suggested to play a role in
the regulation of neurotransmitter release (Burre et al., 2010).
Mainly, it has been demonstrated that α-synuclein can interact
with the components of the SNAP (Soluble NSF Attachment
Protein) Receptor (SNARE) complex in the presynapse, e.g.,
synaptobrevin-2 (Burre et al., 2010), synapsin III (Zaltieri et al.,
2015) and rab3A (Chen et al., 2013; reviewed in Burre, 2015).
In addition, α-synuclein can be found also at other cellular
locations, such as the cytosol and mitochondria (Chinta et al.,
2010).
More recently, it has been demonstrated that α-synuclein
also can be secreted and transferred to nearby cells (Li et al.,
2008; Hansen et al., 2011). Such cell-to-cell transfer provides
an attractive explanation for the hierarchical spreading of Lewy
pathology within the central nervous system (CNS) (Braak
et al., 2003) and to the more recent question why the presence
of α-synuclein in neuronal plexa of the intestinal wall seems
to precede the formation of brain inclusions (Braak et al.,
2006). The underlying mechanisms for such propagation of
pathological α-synuclein have only been partially elucidated, but
seem to involve retrograde transport (Holmqvist et al., 2014)
as well as release via exosomes and other extracellular vesicles
(Emmanouilidou et al., 2010; Bellingham et al., 2012; Danzer
et al., 2012).
FEATURES OF PHYSIOLOGICAL
α-SYNUCLEIN
Different studies have come to different conclusions regarding
the properties of physiological α-synuclein. One research group
has proposed that the normal cellular state of the protein
is a tetrameric complex, which needs to dissociate before
the monomers can start to aggregate (Bartels et al., 2011;
Dettmer et al., 2013). However, in a large multicenter study it
could be demonstrated that α-synuclein predominantly exists
as an unfolded monomer, at least in the CNS (Fauvet et al.,
2012). Moreover, a recent investigation lends further support
to this notion and also provides detailed information of the
structure and post-translational modifications of the α-synuclein
monomer (Theillet et al., 2016). Most importantly, this study
indicates that physiological α-synuclein monomers are amino-
terminally acetylated and thereby adopt a compact conformation.
As a consequence, mid region epitopes critical for the assembly
of α-synuclein into multimers should then be protected from
the cytoplasmic exposure needed for spontaneous aggregation
(Theillet et al., 2016).
THE α-SYNUCLEIN CASCADE
HYPOTHESIS
In addition to the clinicopathological correlation, i.e., the
finding of α-synuclein-containing pathology in affected brain
areas, genetic evidence strongly support the α-synuclein cascade
hypothesis—that the formation of aggregating α-synuclein
species precedes synaptic dysfunction and subsequent neuronal
death (reviewed in Houlden and Singleton, 2012). As for
several other neurodegenerative diseases, molecular genetic
findings have been crucial to further our understanding of the
pathophysiology. To date, six point mutations (Polymeropoulos
et al., 1997; Conway et al., 1998; Kruger et al., 1998; Zarranz
et al., 2004; Appel-Cresswell et al., 2013; Lesage et al., 2013;
Proukakis et al., 2013), as well as duplications (Chartier-Harlin
et al., 2004) and triplications (Singleton et al., 2003) of the
α-synuclein gene have been identified. All of these mutations
lead to early-onset forms of familial α-synucleinopathy, with
a seemingly very high penetrance (reviewed in Houlden and
Singleton, 2012).
At least two of the α-synuclein mutations, A30P and A53T,
were early shown to promote an increased formation of large
soluble oligomers—or protofibrils—which was suggested to be
their pathophysiological mechanism (Conway et al., 2000). These
observations have been followed by numerous ex vivo and in vivo
studies, supporting that the oligomers exert more pronounced
neurotoxic effects than the fibrils per se. Interestingly, a recent
study identified different structures between mutant and wild-
type α-synuclein oligomers, suggesting that pathology may
be related not only to the amount of oligomers but also to
the structural and functional properties of the species formed
(Tosatto et al., 2015).
Thus, the formation of oligomeric species can be regarded as a
central event in the α-synuclein cascade hypothesis (Figure 2).
Whereas, the appearance of these intermediately sized, soluble
aggregates precede the formation of Lewy bodies and Lewy
neurites (on pathway oligomers)—or if they are arrested in
an oligomeric state (off pathway oligomers) has not been
clarified.
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FIGURE 2 | The α-synuclein cascade hypothesis. The aggregation of α-synuclein presumably starts with a conformational shift of the monomeric protein, followed
by the step-wise formation of larger multimeric protein species. Evidence suggest that soluble oligomeric / protofibrillar aggregates are the most neurotoxic forms of
α-synuclein. Such species, as well as the ready-formed fibrils, may also potentiate pathology by acting as seeds for the formation of additional aggregates.
ALPHA-SYNUCLEIN OLIGOMERS
Increased levels of differently sized α-synuclein oligomers have
been measured in brains with Lewy pathology compared to
brains from non-diseased individuals (Sharon et al., 2003;
Kramer and Schulz-Schaeffer, 2007; Paleologou et al., 2009).
Furthermore, several studies have described elevated levels of
oligomeric α-synuclein in cerebrospinal fluid (CSF) in PD
patients compared to control subjects (Tokuda et al., 2006; Park
et al., 2011; Aasly et al., 2014; Hansson et al., 2014; Parnetti
et al., 2014). All of the CSF studies have adopted an ELISA
based on the monoclonal α-synuclein antibody 211 as capture
antibody and its biotinylated version as reporter antibody. Such
an approach avoids detection of monomeric α-synuclein, but
cannot distinguish between the different multimeric forms.
Additional proof of concept studies have demonstrated the
feasibility of using antibodies that can selectively measure
particular disease-related oligomeric species (Sierks et al., 2011;
Brannstrom et al., 2014; Unterberger et al., 2014), but no larger
case-control studies based on such antibodies have so far been
reported.
In addition to these direct clinical and clinico-pathological
observations, a large number of studies have investigated the
physiological effects of α-synuclein oligomers on various cellular,
tissue and animal models. For ex vivo studies large α-synuclein
oligomers (with a size ≥ 600 kDa) can be generated from
recombinant protein. Although, the concentration of protein
needs to be high (≥ 200 µM), the oligomeric yield is typically
low (less than 15% of the starting material, Lashuel et al., 2002).
Also, the resulting oligomers are typically prone to degradation.
However, by using certain molecular agents, more structurally
stable α-synuclein oligomer can be induced (Lashuel et al.,
2002).
IN VITRO GENERATION OF α-SYNUCLEIN
OLIGOMERS
Several protocols, by which recombinant α-synuclein can be
oligomerized, have been described. For example, polyphenol(-)-
epigallocatechin gallate, baicalein, nicotine, dopamine, H2O2
and 3,4-dihydroxyphenylacetic acid have all been used to
promote α-synuclein oligomerization in vitro (Cappai et al., 2005;
Ehrnhoefer et al., 2008; Hong et al., 2008, 2009; Zhou et al., 2009,
2010; Bieschke et al., 2010). In addition, oxidativemodification by
e.g., methionine oxidation of α-synuclein also induces oligomer
formation (Uversky et al., 2002). However, most of thesemodified
oligomers lack a distinct secondary structure and have an off
pathway character. Typically, they either inhibit the formation
of fibrils or disassemble already formed fibrils and are usually
non-toxic.
Various molecules involved in oxidative stress have been
described to induce α-synuclein oligomerization. Mainly, the
reactive aldehyde 4-hydroxy-2-nonenal (HNE) was found to
covalently modify α-synuclein in vitro and thereby induce
stable β-sheet-rich oligomers with neurotoxic properties (Qin
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et al., 2007). Also other aldehydes, such as acrolein and
4-oxo-2-nonenal (ONE), have been shown to induce α-synuclein
oligomerization (Shamoto-Nagai et al., 2007; Näsström et al.,
2009). Although, the direct link between oxidative stress and α-
synuclein aggregation is unknown, short-lived reactive oxygen
species, known to initiate lipid peroxidation of polyunsaturated
fatty acids, have been shown to be present in neuronal cell
membranes. Such peroxidation can lead to the formation
of reactive aldehydes which, in addition to being cytotoxic
themselves, can bind covalently both to α-synuclein and to other
proteins and thereby alter their normal structure and function
(Esterbauer et al., 1991).
PROPOSED MECHANISMS BEHIND
α-SYNUCLEIN MEDIATED TOXICITY
In the following, some of the proposed intra- and extracellular
consequences of toxic α-synuclein oligomers will be discussed.
Their potential targets and effects are summarized in Figures 3, 4.
General Cellular Toxicity
Using various forms of in vitro generated α-synuclein, several
ex vivo and in vivo studies have found that such species
have pronounced toxic effects on cells. In one study it was
demonstrated that in vitro generated large α-synuclein oligomers
could induce cellular pathology (Danzer et al., 2007). Upon
generation and characterization of various types of oligomers, all
were shown to have various damaging effects on cells in culture.
One variant was proposed to induce cell death via disruption of
cellular ion homeostasis by a pore-forming mechanism, whereas
another was able to directly enter cells and cause increased
protein aggregation (Danzer et al., 2007). A subsequent study
used a cell model for α-synuclein oligomerization and found that
induction of oligomers resulted in increased cell toxicity (Outeiro
et al., 2008).
When exposing lower organisms, like c. elegans and
d. melanogaster, to in vitro generated α-synuclein oligomers,
pronounced neurotoxic effects could be demonstrated
(Karpinar et al., 2009) Also, in a study on transgenic mice
it was found that mice expressing the artificial α-synuclein
FIGURE 3 | Proposed intracellular targets for α-synuclein mediated toxicity. Alpha-synuclein oligomers may mediate toxicity via several intracellular targets.
Mainly, impairment of various protein degradation pathways as well as damage of the mitochondria and endoplasmic reticulum have been suggested.
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FIGURE 4 | Proposed extracellular targets for α-synuclein mediated toxicity. Recent studies indicate that α-synuclein oligomers/protofibrils can propagate
between neurons as either free floating proteins or via exosomes / other extracellular vesicles. Release and uptake of such species seem to occur either at the cell
body or at the synapse. Also glial cells, such as astrocytes, may be involved in this process.
variants E57K and E35K, engineered to promote oligomer
formation, displayed a more severe loss of dopaminergic
neurons as compared to regular α-synuclein transgenic
mice, overexpressing wild-type α-synuclein (Winner et al.,
2011).
Compromised Cell Membrane Integrity
Several observations suggest that α-synuclein oligomers, similar
to certain protein toxins, can disrupt cellular homeostasis by
creating pores in the cell membrane. A disruption of the outer
lipid bilayer can cause an increased permeability and influx of
ions from the extracellular space (Volles et al., 2001; Volles
and Lansbury, 2002; Danzer et al., 2007). In one of these
studies, oligomers with such properties could be induced by
incubating recombinant α-synuclein for 6 days in a sodium
phosphate buffer, followed by exposure to iron. The formed
oligomers were shown to form pores in a synthetic bilayer
assay. Moreover, when exposing these protofibril-shaped species
to primary cortical neurons they caused a depolarization of
the cell membrane, presumably due to iron fluxes through
the membrane.
Synaptic Toxicity/Deficient Neuronal
Signaling
Since evidence suggest that α-synuclein plays a role in the
regulation of the SNARE-complex at the synapse (reviewed in
Burre, 2015), it has been speculated that oligomeric α-synuclein
may perturb this function and thereby cause a direct synaptotoxic
effect (Choi et al., 2013).
In one study on hippocampal brain slices from rats,
exogenously added α-synuclein oligomers were found to have
a negative impact on neuronal signaling (Diogenes et al.,
2012). Tissues that had been pre-incubated with α-synuclein
oligomers displayed an increase in synaptic transmission leading
to a suppression of long term potentiation, as determined
by extracellular recordings of excitatory postsynaptic potential
(EPSPs) from Schaeffer-collaterals/CA1 glutamatergic fibers.
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However, when monomeric or fibrillar α-synuclein species
were added at similar concentrations, no such effects could
be observed. The synaptic dysregulation seemed to depend on
the presence of N-Metyl-D-Aspartate (NMDA) receptors, as the
effects could be avoided by selectively blocking this glutamate
receptor subtype (Diogenes et al., 2012).
In a more recent study, two different types of oligomers
were generated either by polymerization of monomers or by
sonication of fibrils (Kaufmann et al., 2016). Although, the
structure of these species differed somewhat, they were both
found to have a negative impact on neuronal excitability as
indicated by patch-clamp recordings of pyramidal neurons in
neocortical brain slices from mouse (Kaufmann et al., 2016).
Alpha-synuclein oligomer-induced synaptic dysfunction has
also been suggested in vivo. Extensive synaptic and dendritic
loss, in parallel with a reduction in synapsin 1 and synaptic
vesicles, could be demonstrated on mice expressing the artificial
and oligomerization prone α-synuclein mutation E57K under the
Thy-1 promoter (Rockenstein et al., 2014). Thus, these findings
suggest that accumulating oligomeric α-synuclein may mediate
early synapse-related pathology by disrupting synaptic vesicles in
CNS neurons.
Impairment in Intracellular Degradation
Failure in protein degradation pathways, such as the ubiquitin-
proteasome system or the autophagy-lysosomal pathway, has
in several investigations been implicated as a consequence of
α-synuclein oligomer formation. One study found increased
cellular toxicity, as measured by the release of adenylate kinase
and increase of the apoptotic marker caspase-3, upon lysosomal
inhibition by bafilomycin, whereas activation of the lysosomes by
rapamycin resulted in decreased toxicity (Klucken et al., 2012).
Interestingly, the bafilomycin-induced toxicity was paralleled by
a decrease in fibril formation, whereas the levels of insoluble
smaller species increased, suggesting that α-synuclein oligomers
may have mediated the toxic effects observed (Klucken et al.,
2012).
Defects in phagocytosis have also been suggested as a disease-
causing mechanism for α-synucleinopathies. In particular,
uptake and subsequent degradation of α-synuclein oligomers
by microglia and astrocytes may be an important mechanism
for the prevention and/or clearance of pathology. Such an
impairment may be related to various inherent factors and
lead to disease susceptibility in certain individuals. Recently, it
could be demonstrated that cultured microglia from adult mice
displayed a less efficient uptake and clearance of oligomeric α-
synuclein as compared to younger mice. Similar effects could
be demonstrated when analyzing peripheral monocytes from
older vs. younger human subjects (Bliederhaeuser et al., 2016).
Taken together, these findings suggest that there might be an age-
dependent deficit in the uptake and clearance of toxic α-synuclein
by phagocytic cells.
Mitochondrial Toxicity
One study found that overexpression of the oligomer-promoting
α-synuclein mutants A53T and A30P in human neuroblastoma
cells augmented aggregation of α-synuclein (Parihar et al.,
2009). Immuno-gold electron transmission microscopy
showed localization of the α-synuclein aggregates within the
mitochondria of overexpressing cells, which displayed decreased
mitochondrial transmembrane potential as well as compromised
cellular respiration (Parihar et al., 2009). More recently, it could
be demonstrated that α-synuclein oligomers can prevent the
import of proteins into the mitochondria of cultured cells by
interacting with the translocase of the outer membrane 20 (TOM
20) and thereby disrupt its normal association with TOM 22.
The functional relevance of such a mechanism was indicated
by the finding of decreased amounts of Ndufs3, a complex I
subunit of the respiratory chain, in the mitochondria of cells that
had been exposed to oligomers, whereas no such effect could be
seen for cells that had been subjected to monomers or fibrils of
α-synuclein. Interestingly, it was also found that substantia nigra
from PD brains displayed a pronounced molecular interaction
between α-synuclein and TOM 20 as well as decreased levels of
Ndufs3, as compared to control brains (Di Maio et al., 2016).
Dysfunction of the Endoplasmic Reticulum
It has been shown that accumulation of α-synuclein
oligomers/protofibrils in the endoplasmic reticulum (ER) leads
to ER stress, which may contribute to neurodegeneration (Colla
et al., 2012b). The same authors found that induction of the ER
chaperones grp94, grp78 and PDI in affected neurons of the brain
stem and spinal cord coincided with the onset of symptoms in an
α-synuclein A53T transgenic mouse model (Colla et al., 2012a).
Moreover, the study described data suggesting that salubrinal,
an inhibitor of the eIF2α phosphatase, could attenuate the
accumulation of toxic α-synuclein oligomers (Colla et al., 2012b)
and reduce oligomeric microsomal accumulation in microsomes,
vesicle-like structures formed from the ER, in treated mice (Colla
et al., 2012a).
Inflammatory Responses
The role of inflammation in the neurodegenerative brain is
only partly understood, but seems to involve both protective
and damaging effects. Whereas, the removal of dead cells
and debris depend upon phagocytosis by microglia and/or
astrocytes an increased release of cytokines can, under certain
circumstances, cause neuronal dysfunction and cell death. As
for α-synuclein, aggregated extracellular species have been
shown to activate microglia and thereby cause inflammation
and degeneration of affected neurons (Zhang et al., 2005;
Wilms et al., 2009). In a primary mesencephalic neuron-
glia culture system, activation of microglia was found to
enhance dopaminergic neurodegeneration induced by such
α-synuclein species. Moreover, it was proposed that the glia-
mediated enhancement of the neurotoxicity was depending
on phagocytosis of α-synuclein, leading to the activation of
NADPH oxidase and generation of reactive oxygen species
(Zhang et al., 2005). In another study, subjecting cultured
microglial cells to α-synuclein protofibrils, proinflammatory
signaling pathways involving p38, ERK1/2 MAP kinases and
NF-κB became activated. In addition, injection of α-synuclein
protofibrils into substantia nigra of adult rats resulted in a
profound activation of microglia together with adjacent neuronal
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cell loss, which could be attenuated by the MAP kinase inhibitor
semapimod (Wilms et al., 2009).
Thus, several studies suggest that oligomeric/protofibrillar
α-synuclein may exert some of its toxic effects by promoting
reactions that could enhance the inflammatory response in the
affected tissue. Especially microglia seem to be particularly prone
to react upon exposure of such α-synuclein species and future
studies will elucidate whether also astrocytes may contribute
to damaging inflammatory responses elicited by α-synuclein
oligomers/protofibrils.
Seeding/Cell-to-Cell Propagation
The growing realization that α-synuclein pathology can be
propagated between cells imply that abnormal species can
induce conformational changes and aggregation of physiological
monomeric protein. Such seeding effects have been linked to
α-synuclein oligomers. The first observation suggesting cell-
to-cell spreading of α-synuclein was made at autopsy of PD
brains that 10–15 years earlier had received fetal dopaminergic
grafts as an experimental therapeutic approach. The researchers
found that not only the host tissue, but also the graft,
displayed Lewy pathology, suggesting that abnormal α-synuclein
had been transferred from the affected host to the engrafted
tissue (Kordower et al., 2008; Li et al., 2008; Mendez et al.,
2008). Subsequent studies have investigated the underlying
mechanisms and found that the α-synuclein oligomers seem
to play a central role in these processes (Hansen et al.,
2011).
In vitro-generated α-synuclein oligomers have been shown
to induce transmembrane seeding of α-synuclein aggregation
in primary neuronal cultures as well as in neuronal cell lines
(Danzer et al., 2009). Thus, such extracellular α-synuclein
oligomers seem to have the capacity to induce intracellular
α-synuclein aggregation and could thus be responsible for
spreading the disease between interconnected cells. The
same research group could also demonstrate that α-synuclein
oligomers are especially prone to get secreted in exosomes and
that the presence of oligomers in such extracellular vesicles can
mediate the intercellular spreading of α-synuclein pathology
(Danzer et al., 2012).
Moreover, also non-neuronal cells may be involved in the
cell-to-cell spreading of α-synuclein pathology. For example,
cell culture-based studies suggest that astrocytes may internalize
α-synuclein from neurons by endocytosis (Lee et al., 2010).
Apart from generating inclusion bodies and induction of pro-
inflammatory cytokines, such an uptake could promote further
propagation of pathological α-synuclein.
TOXIC α-SYNUCLEIN OLIGOMERS AS A
THERAPEUTIC TARGET
Immunotherapy has emerged as a promising method to target α-
synuclein pathology. When α-synuclein fibrils were peripherally
administered on mice or rats expressing human α-synuclein, a
reduced protein deposition in their brains could be seen (Masliah
et al., 2005; Sanchez-Guajardo et al., 2013). Moreover, passive
immunization with monoclonal α-synuclein antibodies on mice
have also proven efficacious to both decrease pathology, to
ameliorate symptoms and to prevent cell-to-cell propagation of
pathology (Masliah et al., 2011; Bae et al., 2012; Games et al.,
2014).
As accumulating evidence suggest that α-synuclein
oligomers/protofibrils are responsible for the neurotoxicity
in Lewy body disorders, researchers have begun to selectively
target such species for immunotherapy, either by active or passive
immunotherapy. By immunizing transgenic α-synuclein mice
with certain peptides that mimic the c-terminus of α-synuclein
and result in antibodies with oligomer-selective properties a
reduced pathology as well as an improved outcome on motor
tests were observed (Mandler et al., 2014).
We generated a large oligomeric form of α-synuclein and
could demonstrate that this species had various toxic effects
on ex vivo models (Nasstrom et al., 2011; Diogenes et al.,
2012; Fagerqvist et al., 2013b). This α-synuclein species was
also used as antigen to generate monoclonal antibodies with
a pronounced oligomer/protofibril selectivity (Fagerqvist et al.,
2013a). Initially, we used these antibodies to assess levels of
α-synuclein oligomers/protofibrils in the CNS of α-synuclein
transgenic mice and found that mice expressing high levels
developed motor symptoms at an earlier stage than mice
expressing low levels (Lindstrom et al., 2014). Next, we treated
the mice with repeated intraperitoneal injections of one of
these antibodies, resulting in reduced levels of α-synuclein
in the CNS (Lindstrom et al., 2014). Ongoing studies will
show whether such a treatment also can alleviate the motor
and behavioral symptoms that the transgenic mice normally
develop.
The prospect of using peripheral immunotherapy to target α-
synuclein oligomers/protofibrils is a daunting task, regardless of
whether one is taking the active or the passive immunization
approach. Firstly, we still do not know by which means and
via which mechanisms that the antibodies act. Secondly, the
antibodies have to pass the blood brain barrier in sufficient
amounts to exert an effect in the CNS. Thirdly, the antibodies
probably have to reach into the cells (where most of the
α-synuclein pathology is present) and at the same time avoid
the normal, physiological forms of the protein. One attempt
to increase the intracellular presence of therapeutic antibodies
inside CNS is represented by virus-mediated delivery. In one
recent study, lentivirus expressing oligomer-selective single
chain α-synuclein antibodies were shown to be efficacious on
transgenic mice, both with respect to pathology and motor
symptoms (Spencer et al., 2016). Future studies with similar
approaches will be needed to optimize delivery and expression
of such “intrabodies.”
In spite of the remaining challenges and questions,
sufficient evidence demonstrating the feasibility of α-synuclein
immunization have been provided. The first clinical studies
on humans, adopting α-synuclein immunotherapy, are already
underway and the outcome of these will provide us with new
knowledge that hopefully will help us in the development of a
therapy that can efficiently alleviate both the pathology and the
symptoms that patients with Lewy body disorders suffer from.
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CONCLUSIONS
Molecular genetic and biochemical evidence support the
hypothesis that α-synuclein oligomers play a central role in the
pathogenesis of Parkinson’s disease and related disorders. Several
intra- and extracellular mechanisms, by which such prefibrillar
species of α-synuclein exert damaging effects, have been
identified (Figures 3, 4). Apart from general cellular toxicity,
mitochondrial stress, synaptic dysfunction and compromised
cell membrane integrity are some examples of the proposed
pathogenic mechanisms. Moreover, oligomers of α-synuclein
can act as seeds for the formation of aggregates and also
seem to be prone to transfer between cells. Taken together,
the properties of α-synuclein oligomers indicate that they
are particularly responsible for the propagation of pathology
and that such species should be suitable targets for early
therapeutic intervention in Parkinson’s disease and related
disorders.
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